THC — Tenet Healthcare Corporation

Tenet Healthcare (THC) Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Net Operating Revenues: $5.3 billion, exceeding expectations.
• Adjusted EBITDA: $1.1 billion, up 12% year-over-year, with an adjusted EBITDA margin of 20.8%, reflecting a 170 basis points improvement.
• USPI Segment: Adjusted EBITDA of $492 million, also up 12% year-over-year, with same-facility revenues growing by 8.3%.
• Hospital Segment: Adjusted EBITDA of $607 million, a 13% increase, with same-store admissions up 1.4% and revenue per adjusted admission rising by 5.9%.
• Free Cash Flow: Generated $778 million in Q3, totaling $2.16 billion year-to-date, a 22% increase from the prior year.

2. Strategic Updates and Business Highlights

• M&A Activity: Acquired 11 centers and opened 2 de novo centers, focusing on high-acuity procedures. Nearly $300 million spent on M&A year-to-date, with plans for further acquisitions.
• New Hospital Opening: A new facility in Port St. Lucie, Florida, was launched, enhancing capacity in a rapidly growing area.
• Operational Efficiency: Continued improvements in salary, wages, and benefits, which constituted 41.7% of net revenues, a 160 basis points improvement from the previous year.

3. Forward Guidance and Outlook

• Adjusted EBITDA Guidance: Increased to $4.47 billion to $4.57 billion for the full year 2025, reflecting an 11% increase at the midpoint from initial guidance.
• Capital Expenditures: Expected to range from $875 million to $975 million, a $150 million increase at the midpoint, aimed at supporting organic growth.
• Free Cash Flow Guidance: Raised to $1.495 billion to $1.695 billion for 2025, driven by strong cash collection performance and EBITDA growth.

4. Bad News, Challenges, or Points of Concern

• Exchange Subsidy Uncertainty: There is ongoing uncertainty regarding the impact of enhanced premium tax subsidies on reimbursement and enrollment in exchanges, which could affect future revenues.
• Potential Decline in Utilization: While the company has not built in expectations for increased utilization due to subsidy expirations, there is a risk of reduced patient volumes if these subsidies are not renewed.
• Inflationary Pressures: Although labor costs have been managed well, there are concerns about potential inflationary pressures and tariffs impacting future expenses.

5. Notable Q&A Insights

• Utilization Expectations: Management indicated no rush in patient volumes related to exchange subsidies and expressed confidence in USPI's capacity to handle typical demand increases in Q4.
• M&A Environment: The competitive landscape for ASC acquisitions remains robust, with Tenet positioned as a preferred partner due to its track record and operational capabilities.
• Conifer Performance: Conifer's cash collection capabilities have been strong, contributing positively to free cash flow, with plans to enhance its role in patient eligibility and enrollment services amid potential changes in exchange subsidies.
• Labor Environment: The labor market remains favorable, with no significant changes anticipated for 2026, although management remains vigilant regarding inflationary pressures and operational efficiencies.

This summary encapsulates Tenet Healthcare's financial performance, strategic initiatives, and outlook while highlighting potential challenges and insights from the Q&A session.